Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MYD88 L265P + BRAF V600E

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

HER-2 amplification + RAS wild-type + BRAF wild-type (9)

BRAF V600K + LDH elevation (3)

BRAF V600E + MSI-H (2)

BRAF V600E + PD-L1 expression (2)

BRAF V600E + PD-L1 expression (2)

BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR (2)

BRAF V600E + ROS1 fusion (2)

BRAF mutation + MET amplification (2)

BRAF mutation + MSI-L/dMMR (2)

BRAF mutation + TERT overexpression (2)

BRAF wild-type + HER-2 positive (2)

EZR overexpression + BRAF V600E (2)

IDH1 mutation + BRAF V600E (2)

IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

IDH2 mutation + BRAF V600E (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

MSI-H/dMMR + BRAF V600E (2)

PD-L1 expression + NRAS Q61R + BRAF D594N (2)

PD-L1 overexpression + BRAF V600E (2)

RAS wild-type + BRAF wild-type + HER-2 positive (2)

ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)

ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)

BRAF E501Q + PD-L1 negative (1)

BRAF V600 + LDH elevation (1)

BRAF V600 + LDH elevation + PD-L1 negative (1)

BRAF V600E + CDKN2A deletion + MYCN amplification (1)

BRAF V600E + CDKN2A deletion + RB1 expression (1)

BRAF V600E + EGFR expression (1)

BRAF V600E + PTEN deletion (1)

BRAF V600E + SOX2 amplification (1)

BRAF V600K + CDKN2A deletion + RB1 expression (1)

BRAF mutation + PD-L1 overexpression (1)

BRAF mutation + TMB-H (1)

BRAF mutation + TMB-L + MSI-L/dMMR (1)

BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion (1)

BRAF wild-type + HGF elevation (1)

CD8 elevation + BRAF V600 (1)

Chr t(11;14) + BRAF mutation (1)

EGFR exon 19 deletion + BRAF G464A (1)

EGFR overexpression + BRAF V600E (1)

EGFR overexpression + BRAF mutation (1)

HER-2 amplification + BRAF wild-type (1)

HR positive + BRAF V600E (1)

KIAA1549-BRAF fusion + MET amplification (1)

KIAA1549-BRAF fusion + PTEN deletion (1)

KRAS wild-type + BRAF V600E (1)

LDH elevation + BRAF mutation (1)

MAP2K1 mutation + BRAF wild-type (1)

MSI-H/dMMR + BRAF Mutation (1)

MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)

NRAS mutation + BRAF wild-type (1)

PD-L1 expression + BRAF negative (1)

PIK3CA mutation + BRAF wild-type (1)

SEMA6A overexpression + BRAF mutation (1)

SRC overexpression + BRAF V600E (1)

TNFAIP3 overexpression + BRAF mutation (1)

MYD88 mutation + DUSP22 expression (1)

MYD88 mutation + GPER1 expression (1)

MYD88 mutation + PRDM15 expression (1)

MYD88 mutation + TNIK expression (1)

MYD88 mutation + WNK2 expression (1)

PD-L1 overexpression + BRAF mutation (0)

HER-2 amplification + RAS wild-type + BRAF wild-type (9)

BRAF V600K + LDH elevation (3)

BRAF V600E + MSI-H (2)

BRAF V600E + PD-L1 expression (2)

BRAF V600E + PD-L1 expression (2)

BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR (2)

BRAF V600E + ROS1 fusion (2)

BRAF mutation + MET amplification (2)

BRAF mutation + MSI-L/dMMR (2)

BRAF mutation + TERT overexpression (2)

BRAF wild-type + HER-2 positive (2)

EZR overexpression + BRAF V600E (2)

IDH1 mutation + BRAF V600E (2)

IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

IDH2 mutation + BRAF V600E (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

MSI-H/dMMR + BRAF V600E (2)

PD-L1 expression + NRAS Q61R + BRAF D594N (2)

PD-L1 overexpression + BRAF V600E (2)

RAS wild-type + BRAF wild-type + HER-2 positive (2)

ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)

ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)

BRAF E501Q + PD-L1 negative (1)

BRAF V600 + LDH elevation (1)

BRAF V600 + LDH elevation + PD-L1 negative (1)

BRAF V600E + CDKN2A deletion + MYCN amplification (1)

BRAF V600E + CDKN2A deletion + RB1 expression (1)

BRAF V600E + EGFR expression (1)

BRAF V600E + PTEN deletion (1)

BRAF V600E + SOX2 amplification (1)

BRAF V600K + CDKN2A deletion + RB1 expression (1)

BRAF mutation + PD-L1 overexpression (1)

BRAF mutation + TMB-H (1)

BRAF mutation + TMB-L + MSI-L/dMMR (1)

BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion (1)

BRAF wild-type + HGF elevation (1)

CD8 elevation + BRAF V600 (1)

Chr t(11;14) + BRAF mutation (1)

EGFR exon 19 deletion + BRAF G464A (1)

EGFR overexpression + BRAF V600E (1)

EGFR overexpression + BRAF mutation (1)

HER-2 amplification + BRAF wild-type (1)

HR positive + BRAF V600E (1)

KIAA1549-BRAF fusion + MET amplification (1)

KIAA1549-BRAF fusion + PTEN deletion (1)

KRAS wild-type + BRAF V600E (1)

LDH elevation + BRAF mutation (1)

MAP2K1 mutation + BRAF wild-type (1)

MSI-H/dMMR + BRAF Mutation (1)

MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)

NRAS mutation + BRAF wild-type (1)

PD-L1 expression + BRAF negative (1)

PIK3CA mutation + BRAF wild-type (1)

SEMA6A overexpression + BRAF mutation (1)

SRC overexpression + BRAF V600E (1)

TNFAIP3 overexpression + BRAF mutation (1)

MYD88 mutation + DUSP22 expression (1)

MYD88 mutation + GPER1 expression (1)

MYD88 mutation + PRDM15 expression (1)

MYD88 mutation + TNIK expression (1)

MYD88 mutation + WNK2 expression (1)

PD-L1 overexpression + BRAF mutation (0)

›

over2years

Clinicopathological features and BRAF V600E and MYD88 L265P mutation status of nodal marginal zone lymphoma (PubMed, Zhonghua Bing Li Xue Za Zhi)

No MYD88 L265P mutation is found in NMZL. Some cases may harbor BRAF V600E mutation and yet the prevalence remains indeterminate; further researches are warranted.

over 2 years ago

Journal • IO biomarker

|

BRAF (B-raf proto-oncogene) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD5 (CD5 Molecule) • SPN (Sialophorin)

|

BRAF V600E • BRAF V600 • MYD88 L265P • CD20 expression • MYD88 L265P + BRAF V600E

over3years

New developments in non-Hodgkin lymphoid malignancies. (PubMed, Pathology)

Breast implant-associated anaplastic large cell lymphoma is a new provisional entity with indolent behaviour. Finally, cutaneous T-cell proliferations include a new provisional entity, primary cutaneous acral CD8-positive T-cell lymphoma, and reclassification of primary small/medium CD4-positive T-cell lymphoma as lymphoproliferative disorder.

over 3 years ago

Review • Journal • IO biomarker

|

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD8 (cluster of differentiation 8) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule) • TP63 (Tumor protein 63)

|

BRAF V600E • BRAF V600 • MYD88 L265P • BCL2 expression • MYC expression • CD8 positive • BCL6 rearrangement • BCL2 rearrangement • MYD88 L265P + BRAF V600E • CD4 positive